Introduction: Human bone marrow stromal cells (hBMSCs) are an attractive source for bone tissue engineering applications because of their proliferative capacity and pluripotency. However, their differentiation potential deteriorates over multiple doubling processes, and they may not be sufficient for clinical applications when an adequate cell number is necessary. Thus, the clinical application of BMSCs requires a more complete understanding of the mechanisms that lead to the deterioration of these cells. We previously demonstrated the importance of quality management procedures for the handling of hBMSCs and provided evidence for the existence of BMSC osteogenic inhibitors whose functions are mediated by cell-cell contact (ORS 2013). One candidate inhibitor is the EphA5 receptor, which is expressed in hBMSCs and up-regulated during long-term culture. This protein is therefore a potential negative prognostic indicator of BMSC quality.
, and hBMSCs at passage 1 (P1) and passage 5 (P5) were stored until further use. When culture plates became 80% confluent, the culture medium of each plate was changed to osteogenic medium containing 10 mM β-glycerophosphate (β-GP) and 50 μg/ml ascorbic acid phosphate (AA) with or without 100 nM dexamethasone (DEX) and/or BMP, and the cells were used for each assay at 0 and 7 days of osteogenic culture. Gene knock-down studies: The EphA5 gene was silenced in BMSCs at P5 using different DNA-modified siRNAs. The overnight culture medium was replaced with osteogenic medium containing β-GP and AA, and the cells were cultured for an additional 72 hrs. Subsequently, total isolated RNA was quantitatively analyzed by real-time PCR (n=7).
Microarray analysis:
The differential gene expression of Dex-untreated BMSCs versus BMSCs treated with Dex for 6 hrs at P5 was analyzed by Affymetrix GeneChip technology for 9 independent BMSC preparations. Evaluation: To evaluate the mRNA expression levels of various markers, total RNA was extracted at days 0 and 7 of differentiation. After reverse transcription of the mRNA into cDNA, real-time PCR was used to quantitatively analyze the mRNA expression levels. Ephrin-Fc and EphA5-Fc treatment: Sub confluent monolayers of cells were incubated with 0, 0.4, or 4 μg/ml Fc, ephrin-Fc, or a recombinant rat EphA5-Fc chimera in DMEM containing 10% fetal bovine serum, 50 μg/ml AA and 10 mM β-GP for the incubated times. The mRNA expression level of ALP at day 7 was measured in P1 and P5 cells (n=4).
Statistical analysis:
The values are expressed as the arithmetic means ± SEM and were analyzed using Student's t-test and oneway ANOVA. Differences were considered significant when the p value was < 0.05.
Results: SiRNA-mediated silencing of EphA5 promotes osteogenic differentiation in hMSCs:
Treatment with EphA5 siRNA led to increases in the ALP and Runx2 expression levels, which indicates that EphA5 is required to suppress the osteoblast phenotype in hBMSCs. Down-regulation of EphA5 also resulted in up-regulated integrin alpha 5 (ITGA5) expression levels.
EphA5 is up-regulated in late culture and down-regulated during osteogenic induction with DEX:
Various subtypes of Eph receptors and their ephrin ligands are expressed in hBMSCs, resulting in their characteristic osteoblast phenotype. Among these subtypes, only EphA5 was up-regulated at P5, and its expression was suppressed by adding osteogenic supplements and DEX ( Figure 1A ). When DEX treatment alone was continued for 72 hr, the mRNA expression levels of only EphA2 and A5 among the ephrin receptor tyrosine kinase subfamily were suppressed, in contrast to BMP treatment, which up-regulated their expression. A synergetic effect of DEX and BMP was observed in this experiment, as demonstrated by increased ALP mRNA expression ( Figure 1B) . DEX treatment led to dramatic changes in cell morphology. The larger ALP-positive subpopulations resulting from continuous DEX treatment indicates that the cell populations have redistributed. We attempted to clarify the mechanism through which DEX promotes hBMSC osteogenic potential by comparing the mRNA expression levels of BMSCs at P5 treated with DEX for 6 hrs with those of untreated BMSCs using microarray analysis. DEX treatment not only up-regulated ITGA5 but also down-regulated EphA5, Rho and RAS-related genes. DEX treatment altered the expression of various interleukins, tumor necrosis factors and chemokine receptors. These dramatic changes caused by DEX induction may be a key to understanding osteogenic differentiation. EphA5 and ITGA5 may be involved in this DEX-mediated osteogenic pathway. DEX may simultaneously negatively regulate EphA5 expression and alter the composition of the hBMSC subpopulations, thus promoting the osteogenic differentiation of hBMSCs. hBMSCs treated with EphA5-Fc express ALP mRNA at levels similar to untreated hMSCs: To understand the opposing effects of EphA5-Fc and ephrin-Fc on the differentiation capacity of hBMSCs, we first used various ephrin-Fc constructs to stimulate Eph forward signaling. Using ephrin-A-Fc, which activates various EphA forward signaling pathways, led to slightly increased ALP mRNA expression levels. Specifically, ephrin-B-Fc significantly increased the ALP mRNA expression levels ( Figure 2A) . We found that the exogenous addition of a soluble EphA5-Fc that was capable of binding to ephrins did not affect ALP mRNA expression levels or activity in either P1 or P5 cells ( Figure 2B ). Ephrin reverse signaling would not be activated by EphA5-Fc or play an important role in the deterioration of hBMSC quality. The inhibition of EphA5 forward signaling caused by EphA5-Fc also did not affect the osteogenic capacity of hMSCs. These results are also consistent with the hypothesis that EphA5 can inhibit osteogenic differentiation independently of its ability to bind ephrin-As. Discussion: Our previous study revealed that long-term passaged BMSCs are capable of forming bone but can also inhibit bone formation. Suppressing these inhibitors is a unique concept for bone regeneration that maintains BMSC quality. We found that the down-regulation of endogenous EphA5 using specific siRNAs or DEX promoted osteoblast marker expression and osteogenic differentiation. We propose that co-expression of EphAs and ephrin-As regulates the osteogenic differentiation capacity of hBMSCs. Under normal conditions, EphA5 and ephrin-As are properly expressed and interact. In later cultures, the frequent increase of dormancy-associated EphA5 may inhibit other expressed EphA or EphB signaling, apparently by direct interaction, although competition for ligand binding may also occur. An imbalance between EphA5 and ligand expression may compromise Eph ligand-dependent hBMSC differentiation and promote the ligand-independent suppressive function. Given the variability of Eph expression in hBMSCs, a more global approach is needed to define the precise role of EphA5. Significance: Understanding the potential inhibitory function of EphA5 expressed in hBMSCs might provide an alternative approach for manipulating the fates of hBMSCs and for differentiating lineages in cell therapeutic strategies and regenerative medicine.
